A case report of cutaneous and systemic lupus erythematosus after bupropion usage

Suat Akgür; Saide Güllülü; Kamil Dilek; Oktay Ünsal; Mehmet Aydın; Ayşegül Oruç; Abdulmecit Yildiz; Mahmut Yavuz; Mustafa Güllülü; Alparslan Ersoy

doi:10.46310/tjim.679421

Olgu Sunumu

A case report of cutaneous and systemic lupus erythematosus after bupropion usage

Yıl 2020, Cilt: 2 Sayı: 3, 91 - 94, 29.07.2020

Suat Akgür , Saide Güllülü Kamil Dilek Oktay Ünsal Mehmet Aydın , Ayşegül Oruç , Abdulmecit Yildiz , Mahmut Yavuz Mustafa Güllülü Alparslan Ersoy

https://doi.org/10.46310/tjim.679421

Cited By: 1

Öz

Bupropion is a drug used to smoke cessation. Various complications have been reported after using this drug. In a 58-year-old female patient, skin findings and anti-Ro52 positivity developed after the use of this drug. Later, signs of vasculitis appeared under immunosuppressive therapy. The patient was diagnosed with cutaneous and systemic lupus erythematosus.

Anahtar Kelimeler

Bupropion, drug reaction, lupus-like syndrome, cutaneous and systemic lupus erythematosus

Kaynakça

1. Sontheimer RD. Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmun Rev. 2005;4(5):253-63.
2. Lin JH, Dutz JP, Sontheimer RD, Werth VP. Pathophysiology of cutaneous lupus erythematosus. Clin Rev Allergy Immunol. 2007;33(1-2):85-106.
3. Marzano AV, Lazzari R, Polloni I, Crosti C, Fabbri P, Cugno M. Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart. Br J Dermatol. 2011;165(2):335-41. doi: 10.1111/j.1365-2133.2011.10397.x.
4. Chong BF, Song J, Olsen NJ. Determining risk factors for developing systemic lupus erythematosus in patients with discoid lupus erythematosus. Br J Dermatol. 2012;166(1):29-35. doi: 10.1111/j.1365-2133.2011.10610.x.
5. Grönhagen CM, Fored CM, Linder M, Granath F, Nyberg F. Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden. Br J Dermatol. 2012;167(2):296-305. doi: 10.1111/j.1365-2133.2012.10969.x.
6. Srivastava M, Rencic A, Diglio G, Santana H, Bonitz P, Watson R, Ha E, Anhalt GJ, Provost TT, Nousari CH. Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus. Arch Dermatol. 2003;139(1):45-9.
7. Callen JP, Hughes AP, Kulp-Shorten C. Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine: a report of 5 cases. Arch Dermatol. 2001;137(9):1196-8.
8. Sontheimer RD, Henderson CL, Grau RH. Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation. Arch Dermatol Res. 2009;301(1):65-70. doi: 10.1007/s00403-008-0890-x.
9. Fays S, Tréchot P, Schmutz JL, Cuny JF, Truchetet F, Barbaud A. Bupropion and generalized acute urticaria: eight cases. Br J Dermatol. 2003;148(1):177-8.
10. Chiavérini C, Baldin B, Chichmanian R-M, Ortonne J-P, Lacour J-P. Bupropion (ZybanÓ) induced urticaria: 2 cases. Annales de Dermatologie et de Vénéréologie. 2003;130(2):208-9. Doi : AD-02-2003-130-2-0151-9638-101019-ART15.
11. Benson E. Bupropion-induced hypersensitivity reactions. Med J Aust. 2001;174(12):650-1.
12. Olsen NJ. Drug-induced autoimmunity. Best Pract Res Clin Rheumatol. 2004;18(5):677-88.
13. Aguirre Zamorano MA1, López Pedrera R, Cuadrado Lozano MJ. Drug-induced lupus. Med Clin (Barc). 2010;135(3):124-9. doi: 10.1016/j.medcli.2009.04.035.
14. Love LA. New environmental agents associated with lupus-like disorders. Lupus. 1994;3(6):467-71.
15. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002;359(9306):579-80.
16. De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, Veys EM, De Keyser F. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum. 2003;48(4):1015-23.
17. Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus. Ann N Y Acad Sci. 2007;1108:166-82.
18. Yung RL, Johnson KJ, Richardson BC. New concepts in the pathogenesis of drug-induced lupus. Lab Invest. 1995;73(6):746-59.
19. Sen D, Isenberg DA. Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus. Lupus. 2003;12(9):651-8.
20. Vasoo S. Drug-induced lupus: an update. Lupus. 2006;15(11):757-61.
21. Jumez N, Dereure O, Bessis D, Guillot B. Flare of cutaneous lupus erythematosus induced by bupropion (Zyban). Dermatology. 2004;208(4):362.
22. Cassis TB, Callen JP. Bupropion-induced subacute cutaneous lupus erythematosus. Australas J Dermatol. 2005 Nov;46(4):266-9.
23. Hannah CE, Little AJ, Wanat KA, Fairley JA. Drug-Induced Cutaneous Lupus Erythematosus: A Case Series of Five Patients with Bupropion-Associated Disease. J Clin Rheumatol. 2018. doi: 10.1097/RHU.0000000000000882.
24. Barile-Fabris L, Hernández-Cabrera MF, Barragan-Garfias JA. Vasculitis in systemic lupus erythematosus. Curr Rheumatol Rep. 2014;16(9):440. doi: 10.1007/s11926-014-0440-9.
25. Ramos-Casals M, Nardi N, Lagrutta M, Brito-Zerón P, Bové A, Delgado G, Cervera R, Ingelmo M, Font J. Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. Medicine (Baltimore). 2006;85(2):95-104.

Yıl 2020, Cilt: 2 Sayı: 3, 91 - 94, 29.07.2020

Suat Akgür , Saide Güllülü Kamil Dilek Oktay Ünsal Mehmet Aydın , Ayşegül Oruç , Abdulmecit Yildiz , Mahmut Yavuz Mustafa Güllülü Alparslan Ersoy

https://doi.org/10.46310/tjim.679421

Cited By: 1

Öz

Kaynakça

1. Sontheimer RD. Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmun Rev. 2005;4(5):253-63.
2. Lin JH, Dutz JP, Sontheimer RD, Werth VP. Pathophysiology of cutaneous lupus erythematosus. Clin Rev Allergy Immunol. 2007;33(1-2):85-106.
3. Marzano AV, Lazzari R, Polloni I, Crosti C, Fabbri P, Cugno M. Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart. Br J Dermatol. 2011;165(2):335-41. doi: 10.1111/j.1365-2133.2011.10397.x.
4. Chong BF, Song J, Olsen NJ. Determining risk factors for developing systemic lupus erythematosus in patients with discoid lupus erythematosus. Br J Dermatol. 2012;166(1):29-35. doi: 10.1111/j.1365-2133.2011.10610.x.
5. Grönhagen CM, Fored CM, Linder M, Granath F, Nyberg F. Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden. Br J Dermatol. 2012;167(2):296-305. doi: 10.1111/j.1365-2133.2012.10969.x.
6. Srivastava M, Rencic A, Diglio G, Santana H, Bonitz P, Watson R, Ha E, Anhalt GJ, Provost TT, Nousari CH. Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus. Arch Dermatol. 2003;139(1):45-9.
7. Callen JP, Hughes AP, Kulp-Shorten C. Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine: a report of 5 cases. Arch Dermatol. 2001;137(9):1196-8.
8. Sontheimer RD, Henderson CL, Grau RH. Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation. Arch Dermatol Res. 2009;301(1):65-70. doi: 10.1007/s00403-008-0890-x.
9. Fays S, Tréchot P, Schmutz JL, Cuny JF, Truchetet F, Barbaud A. Bupropion and generalized acute urticaria: eight cases. Br J Dermatol. 2003;148(1):177-8.
10. Chiavérini C, Baldin B, Chichmanian R-M, Ortonne J-P, Lacour J-P. Bupropion (ZybanÓ) induced urticaria: 2 cases. Annales de Dermatologie et de Vénéréologie. 2003;130(2):208-9. Doi : AD-02-2003-130-2-0151-9638-101019-ART15.
11. Benson E. Bupropion-induced hypersensitivity reactions. Med J Aust. 2001;174(12):650-1.
12. Olsen NJ. Drug-induced autoimmunity. Best Pract Res Clin Rheumatol. 2004;18(5):677-88.
13. Aguirre Zamorano MA1, López Pedrera R, Cuadrado Lozano MJ. Drug-induced lupus. Med Clin (Barc). 2010;135(3):124-9. doi: 10.1016/j.medcli.2009.04.035.
14. Love LA. New environmental agents associated with lupus-like disorders. Lupus. 1994;3(6):467-71.
15. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002;359(9306):579-80.
16. De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, Veys EM, De Keyser F. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum. 2003;48(4):1015-23.
17. Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus. Ann N Y Acad Sci. 2007;1108:166-82.
18. Yung RL, Johnson KJ, Richardson BC. New concepts in the pathogenesis of drug-induced lupus. Lab Invest. 1995;73(6):746-59.
19. Sen D, Isenberg DA. Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus. Lupus. 2003;12(9):651-8.
20. Vasoo S. Drug-induced lupus: an update. Lupus. 2006;15(11):757-61.
21. Jumez N, Dereure O, Bessis D, Guillot B. Flare of cutaneous lupus erythematosus induced by bupropion (Zyban). Dermatology. 2004;208(4):362.
22. Cassis TB, Callen JP. Bupropion-induced subacute cutaneous lupus erythematosus. Australas J Dermatol. 2005 Nov;46(4):266-9.
23. Hannah CE, Little AJ, Wanat KA, Fairley JA. Drug-Induced Cutaneous Lupus Erythematosus: A Case Series of Five Patients with Bupropion-Associated Disease. J Clin Rheumatol. 2018. doi: 10.1097/RHU.0000000000000882.
24. Barile-Fabris L, Hernández-Cabrera MF, Barragan-Garfias JA. Vasculitis in systemic lupus erythematosus. Curr Rheumatol Rep. 2014;16(9):440. doi: 10.1007/s11926-014-0440-9.
25. Ramos-Casals M, Nardi N, Lagrutta M, Brito-Zerón P, Bové A, Delgado G, Cervera R, Ingelmo M, Font J. Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. Medicine (Baltimore). 2006;85(2):95-104.

Toplam 25 adet kaynakça vardır.

Ayrıntılar

Birincil Dil	İngilizce
Konular	İç Hastalıkları
Bölüm	Case Reports
Yazarlar	Suat Akgür 0000-0003-1745-6744 Saide Güllülü Bu kişi benim 0000-0001-6048-1879 Kamil Dilek Bu kişi benim 0000-0001-6149-1913 Oktay Ünsal Bu kişi benim 0000-0002-3215-8457 Mehmet Aydın 0000-0002-5665-7402 Ayşegül Oruç 0000-0002-0342-9692 Abdulmecit Yildiz 0000-0001-5941-9103 Mahmut Yavuz Bu kişi benim 0000-0001-6755-6386 Mustafa Güllülü Bu kişi benim 0000-0002-8911-7189 Alparslan Ersoy 0000-0002-0710-0923
Yayımlanma Tarihi	29 Temmuz 2020
Gönderilme Tarihi	23 Ocak 2020
Kabul Tarihi	28 Nisan 2020
Yayımlandığı Sayı	Yıl 2020 Cilt: 2 Sayı: 3

Kaynak Göster

EndNote	Akgür S, Güllülü S, Dilek K, Ünsal O, Aydın M, Oruç A, Yildiz A, Yavuz M, Güllülü M, Ersoy A (01 Temmuz 2020) A case report of cutaneous and systemic lupus erythematosus after bupropion usage. Turkish Journal of Internal Medicine 2 3 91–94.

Turkish Journal of Internal Medicine

A case report of cutaneous and systemic lupus erythematosus after bupropion usage

Öz

Anahtar Kelimeler

Kaynakça

Öz

Kaynakça

Ayrıntılar

Kaynak Göster

Cited By

Bupropion in dermatology: A brief update

Dermatologic Therapy

https://doi.org/10.1111/dth.14303